IMCR — Immunocore Holdings Balance Sheet
0.000.00%
- $1.51bn
- $1.08bn
- $310.20m
- 50
- 14
- 52
- 32
Annual balance sheet for Immunocore Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | fx Final | fx Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 177 | 322 | 402 | 443 | 820 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 22.8 | 23.2 | 57.1 | 61.4 | 83.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 209 | 355 | 474 | 529 | 930 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 50.4 | 42.7 | 38.8 | 42.7 | 47.7 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 270 | 408 | 527 | 597 | 1,010 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 75.2 | 82.8 | 101 | 139 | 212 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 194 | 176 | 188 | 228 | 649 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 75.7 | 232 | 339 | 369 | 361 |
Total Liabilities & Shareholders' Equity | 270 | 408 | 527 | 597 | 1,010 |
Total Common Shares Outstanding |